To explore the gut microbiome to develop more targeted and effective strategies for the prevention and diagnosis of young colorectal cancer (CRC) patients. With this, we aim to improve the therapeutic outcome and quality of life of CRC patients.
At PerMiCCion, we study the role of the gut microbiome in CRC covering the whole spectrum from Prevention, to Diagnosis, Monitoring, and Treatment.
Our research strategic plan is organized into different sub-projects (SP):
SP1: Improve and explore novel microbiota-driven diagnostics for early-onset CRC
SP2: Unravel the tumor microbiome and mycobiome and its implication for oncogenic signaling
SP3: Prevention of early-onset CRC by dietary and lifestyle modulation of the gut microbiome
SP4: Personalized dietary and lifestyle changes for restoring gut health and improving quality of life in young CRC patients
Our ultimate objective
Develop a microbiome GPS (mGPS) that could inform patients about their microbiome positioning with respect to CRC signature and the healthy gut microbiome, as well as provide personalized dietary and lifestyle choices to restore a healthy microbial gut ecosystem that would improve their quality of life.
Our scientific axis is supported and further enhanced by commercial partners (SMEs) and patient organizations, helping with the exploitation and communication of our research.
PerMiCCion gathers 4 SMEs with a track record in the diagnostic arena, as well as in personalized therapy and preventive medicine. In addition, we work with German and EU-based patient organizations that help us disseminate our research and convey the key message that patients can control and manage effectively their disease symptoms through lifestyle changes.
